China SXT lines up up to $30M in convertible financing to shore up liquidity
What's the deal? China SXT PharmaceuticalsDealroom has a profile for this one. Try Dealroom → agreed on July 3, 2026 to sell up to $30 million in unsecured pre-paid purchases convertible into Class A ordinary shares. The deal starts with a $3.15 million initial closing expected on July 6, with Univest SecuritiesDealroom has a profile for this one. Try Dealroom → acting as placement agent.
The mechanics: The two-year arrangement lets the company draw additional funds over time, with discounted share pricing subject to a $0.20 floor and a 9.99% ownership cap for the investor. Proceeds are earmarked for working capital and general corporate purposes.
Who's raising? China SXT is a British Virgin Islands-based company operating from Taizhou in China's Jiangsu province. It develops and markets pharmaceutical products, including traditional Chinese medicine formulations, and its shares trade on the Nasdaq Capital Market.
Why now? The deal fits a clear pattern rather than a strategic shift. China SXT closed a $10 million registered direct offering with a single investor in January 2026, selling shares or pre-funded warrants at $0.15 each, also via Univest. Earlier raises include a $4.1 million follow-on in 2022.
What could go wrong? The company has leaned heavily on small, dilutive financings to stay funded, and this deal almost certainly implies further dilution for existing holders. SXTC is a volatile micro-cap with weak fundamentals, currently valued near $78.93 million.
The signal: The financing is less about growth and more about balance-sheet survival and Nasdaq compliance. It continues a broader pattern among distressed small-cap China healthcare names using structured pre-funded deals to tap US markets — a tactic investors increasingly treat with skepticism rather than as a growth signal.
Read more: TipRanks
Image credit: jepoirrier
